Skip to main content

Graphite Bio, Inc. (GRPH)

NASDAQ: GRPH · Delayed Price · USD
19.46
+0.09 (0.47%)
After-hours:Sep 17, 2021 7:11 PM EDT
19.37
-0.78 (-3.87%)
At close: Sep 17, 4:00 PM
Market Cap1.12B
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out5.09M
EPS (ttm)-26.68
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,220,916
Open20.03
Previous Close20.15
Day's Range19.37 - 20.44
52-Week Range17.35 - 34.00
Betan/a
Analystsn/a
Price Target34.67 (+79.0%)
Est. Earnings DateNov 11, 2021

About GRPH

Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Our next-generation gene editing platform allows us to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. We believe our approach could enable broad applications to transform human health, including directly correcting mutati...

IndustryBiotechnology
IPO DateJun 25, 2021
CEOJosh Lehrer, M.D.
Employees49
Stock ExchangeNASDAQ
Ticker SymbolGRPH
Full Company Profile

Financial Performance

Financial Statements

News

Graphite Bio Announces Participation in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted ...

2 weeks ago - Business Wire

Graphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing high-efficiency precision gene c...

1 month ago - Business Wire

Graphite Bio's Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish

A differentiated approach to gene editing has ushered a bullish sentiment from BofA Securities and Morgan Stanley on Graphite Bio, Inc. (NASDAQ:GRPH) just a few weeks after its IPO. BofA Securities on G...

1 month ago - Benzinga

Graphite Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purcha...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $GRPH #GraphiteBio--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted ...

2 months ago - Business Wire

Sickle Cell Biotech, Graphite Bio Prices Upsized Initial Public Offering

Graphite Bio Inc (NASDAQ: GRPH) is set to go public on the heels of a $238 million raise less than ten months after getting started with a Series A funding of $45 million.  Graphite is using a familiar ...

2 months ago - Benzinga

Graphite Bio Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure seri...

2 months ago - Business Wire

Graphite Bio IPO Registration Document (S-1)

Graphite Bio, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC